Literature DB >> 16961552

A dollar is a dollar is a dollar--or is it?

Werner B F Brouwer1, N Job A van Exel, Rob M P M Baltussen, Frans F H Rutten.   

Abstract

It is normally stated that an economic evaluation should take the societal perspective and that this implies the incorporation of all costs and effects, regardless of where these occur. Nevertheless, this broad perspective may be in conflict with the narrower perspective of the health-care decision-makers we are usually trying to aid. In this article, it is argued that not all costs have to be considered equally important for health-care decision-making and that there is a discrepancy between the economically preferred societal perspective and the aim of aiding health-care decision-makers. This is related to the concept of local rationality. Three reasons why some costs may be considered more important for health-care decision-makers than others are: 1) relevance; 2) equity; and 3) responsibility. We suggest that it may be useful to adopt a two-perspective approach as a standard, presenting one cost-effectiveness ratio following a strict health-care perspective and one following the common societal perspective. The health-care perspective may assist the health-care policymaker better in achieving health-care goals, while the societal perspective indicates whether the local rationality of the narrow health-care perspective is also in line with societal optimality. More research on actual decisions should provide more insight into the relative weights attached to different types of costs.

Entities:  

Mesh:

Year:  2006        PMID: 16961552     DOI: 10.1111/j.1524-4733.2006.00123.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  25 in total

1.  Justice and the allocation of healthcare resources: should indirect, non-health effects count?

Authors:  Kasper Lippert-Rasmussen; Sigurd Lauridsen
Journal:  Med Health Care Philos       Date:  2010-08

Review 2.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Estimating 'costs' for cost-effectiveness analysis.

Authors:  Alec Miners
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Variation in the methodological approach to productivity cost valuation: the case of prostate cancer.

Authors:  Paul Hanly; Rebecca Maguire; Frances Drummond; Linda Sharp
Journal:  Eur J Health Econ       Date:  2019-08-23

5.  The impact of firms' adjustments on the indirect cost of illness.

Authors:  Michał Jakubczyk; Beata Koń
Journal:  Int J Health Econ Manag       Date:  2017-02-02

6.  When is it too expensive? Cost-effectiveness thresholds and health care decision-making.

Authors:  Werner Brouwer; Pieter van Baal; Job van Exel; Matthijs Versteegh
Journal:  Eur J Health Econ       Date:  2019-03

7.  Korean guidelines for pharmacoeconomic evaluation (second and updated version) : consensus and compromise.

Authors:  Seungjin Bae; Soook Lee; Eun Young Bae; Sunmee Jang
Journal:  Pharmacoeconomics       Date:  2013-04       Impact factor: 4.981

Review 8.  Productivity costs in economic evaluations: past, present, future.

Authors:  Marieke Krol; Werner Brouwer; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981

Review 9.  Estimating productivity costs in health economic evaluations: a review of instruments and psychometric evidence.

Authors:  Kenneth Tang
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

10.  From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.

Authors:  Matthijs Versteegh; Saskia Knies; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.